Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Most Top Drugstore Chains Plan to Continue Dispensing Point Services After October
September 24, 2012
- Prasugrel Achieves Primary Endpoint in Domestic PIII Trial, Expects to Submit NDA in FY2013: Daiichi Sankyo
September 24, 2012
- Novartis to File for Additional Indication for Lucentis in Japan within This Year
September 24, 2012
- Pfizer Preparing for Assault on Domestic Generic Drug Market with Help from Mylan
September 24, 2012
- MTPC Launches Simponi in Indonesia
September 21, 2012
- Nichi-Iko to Set Up New Sections in Sales, Development Divisions to Enhance Oncology Field
September 21, 2012
- Nippon Shinyaku Files for Additional Indication of Chronic Pain for Tramal Capsule
September 21, 2012
- Chugai Applies for Avastin for Recurrent Glioblastoma
September 21, 2012
- Astellas, KEK Announce Collaboration to Develop New Drugs for NTDs
September 21, 2012
- Intellim Establishes Local Office in South Korea, Set to Realize Asian Studies
September 20, 2012
- TS-1 Shows Non-Inferiority to Gemcitabine in Effect on Resected Pancreatic Cancer: Taiho
September 20, 2012
- Symptoms of Cedar Pollen Allergy Reduced in PIII Trial for Sublingual Immunotherapy Drug: Torii
September 20, 2012
- Kitasato Daiichi Sankyo Vaccine to Discontinue Animal Vaccine, to Focus on Human Vaccines
September 20, 2012
- Maruho to Acquire Shares of Maeda Pharmaceutical through Third-Party Allocation
September 20, 2012
- 72% of GPs, 41% of Hospital Doctors Issue Generic Name Prescriptions After April: Sawai Survey
September 20, 2012
- DSP Launches Latuda in Canada
September 19, 2012
- Eli Lilly Japan Applies for Strattera Oral Solution
September 19, 2012
- 60% of Sales to Come from Specialty Field, Oncology by 2017: President Mitani of Novartis Pharma
September 19, 2012
- Janssen Pharmaceutical Discontinues PII Study for Atopic Dermatitis Treatment in Japan
September 19, 2012
- Eisai to Push Efficacy of Careram in Combination with MTX, Low Drug Costs
September 19, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…